ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Saved in:
| Title: | ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. |
|---|---|
| Authors: | Hanson, Amanda1 (AUTHOR), Elpek, Kutlu1 (AUTHOR), Duong, Ellen1 (AUTHOR), Shallberg, Lindsey1 (AUTHOR), Fan, Martin1 (AUTHOR), Johnson, Calvin1 (AUTHOR), Wallace, Matthew2 (AUTHOR), Mabry, George R.2 (AUTHOR), Sazinsky, Stephen2 (AUTHOR), Pepper, Lauren2 (AUTHOR), Shu, Chengyi J.3 (AUTHOR), Sathyanarayanan, Sriram3 (AUTHOR), Zuerndorfer, Sarah2 (AUTHOR), Simpson, Tyler1 (AUTHOR), Gostissa, Monica4 (AUTHOR), Briskin, Michael5 (AUTHOR), Law, Deborah5 (AUTHOR), Michaelson, Jennifer1 (AUTHOR), Harvey, Christopher J.1 (AUTHOR) charvey@jouncetx.com |
| Source: | PLoS ONE. 9/24/2020, Vol. 15 Issue 9, p1-21. 21p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
